Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial.

ABSTRACT:

Background

Biomarker-guided therapies are needed for patients with refractory metastatic colorectal cancer (mCRC). Liquid biopsy (LBx) circulating tumor DNA (ctDNA) comprehensive genomic profiling (CGP) could contribute to the clinical tailoring of molecular targeted therapies for these patients.

Patients and methods

The CAVE-2 GOIM trial is a randomized phase II trial assessing the efficacy of adding avelumab to cetuximab compared with cetuximab monotherapy as anti-epidermal growth factor receptor (EGFR) rechallenge in refractory ctDNA RAS/BRAF^V600E wild-type mCRC patients. Baseline plasma ctDNA CGP was carried out using the Foundation One Liquid CDx.

Results

LBx-based CGP was available for 324 patients out of 328 screened. A total of 1969 pathogenic varia

SUBMITTER: Ciardiello D 

PROVIDER: S-EPMC12242418 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature